ADC Therapeutics To Wind Up Zynlonta Study In Frail Patients After Deaths
Study To End Despite No Clear Link With Treatment
The company had hoped its antibody drug conjugate could help frail and elderly B-cell lymphoma patients ineligible for chemotherapy, but the trial will now close following patient deaths.
